Alvotech (ALVO)
8.53
-0.26 (-2.96%)
At close: Apr 14, 2025, 3:59 PM
8.77
2.90%
After-hours: Apr 14, 2025, 04:05 PM EDT
-2.96% (1D)
| Bid | 8 |
| Market Cap | 2.57B |
| Revenue (ttm) | 465.27M |
| Net Income (ttm) | -231.86M |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | -9.8 |
| Forward PE | 49.28 |
| Analyst | Buy |
| Ask | 9.55 |
| Volume | 67,605 |
| Avg. Volume (20D) | 159,424 |
| Open | 8.80 |
| Previous Close | 8.79 |
| Day's Range | 8.51 - 8.98 |
| 52-Week Range | 7.35 - 14.76 |
| Beta | -0.05 |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque...
Sector Healthcare
IPO Date Jun 16, 2022
Employees 1,012
Stock Exchange NASDAQ
Ticker Symbol ALVO
Website https://www.alvotech.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 111.14% from the latest price.
Stock ForecastsNext Earnings Release
Alvotech is scheduled to release its earnings on May 20, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-10.3%
Alvotech shares are trading lower after the compan...
Unlock content with
Pro Subscription
3 weeks ago
+0.17%
Alvotech shares are trading higher on possible contained strength after the company announced on Thursday a $27 million acquisition deal for Xbrane's R&D operations and its biosimilar candidate XB003.
